Results 331 to 340 of about 17,182,321 (391)

Stem cell therapy for retinal pigment epithelium disorders. [PDF]

World J Stem Cells
Sorrentino FS, Parmeggiani F, Gardini L, Fontana L, Musa M, Gagliano C, Zeppieri M.   +6 more
europepmc   +1 more source

The critical role of DNA damage‐inducible transcript 4 (DDIT4) in stemness character of leukemia cells and leukemia initiation

Molecular Oncology, EarlyView.
Stemness properties, including quiescence, self‐renewal, and chemoresistance, are closely associated with leukemia relapse. Here, we demonstrate that DNA damage‐inducible transcript 4 (DDIT4) is induced in the hypoxic bone marrow niche and is essential for maintaining the stemness of AML1‐ETO9a leukemia cells.
Yishuang Li, Zhijie Cao, Haiyan Xing, Zhenya Xue, Wenbing Liu, Jiayuan Chen, Yihan Mei, Runxia Gu, Hui Wei, Shaowei Qiu, Min Wang, Qing Rao, Jianxiang Wang   +12 more
wiley   +1 more source

Immunomodulatory Effects of Curcumin on CAR T-Cell Therapy. [PDF]

Antioxidants (Basel)
Limsakul P, Srifa P, Huang Z, Zhu L, Wu Y, Charupanit K.   +5 more
europepmc   +1 more source

Unveiling unique protein and phosphorylation signatures in lung adenocarcinomas with and without ALK, EGFR, and KRAS genetic alterations

Molecular Oncology, EarlyView.
Proteomic and phosphoproteomic analyses were performed on lung adenocarcinoma (LUAD) tumors with EGFR, KRAS, or EML4–ALK alterations and wild‐type cases. Distinct protein expression and phosphorylation patterns were identified, especially in EGFR‐mutated tumors. Key altered pathways included vesicle transport and RNA splicing.
Fanni Bugyi, Mirjam Balbisi, Simon Sugár, Lóránd Váncza, Eszter Regős, Ilona Kovalszky, Ibolya Laczó, Tünde Harkó, Gábor Kecskeméti, Zoltán Szabó, Judit Moldvay, László Drahos, Lilla Turiák   +12 more
wiley   +1 more source

Stem cell therapy use in patients with dementia: a systematic review. [PDF]

Int J Emerg Med
Uwishema O, Ghezzawi M, Wojtara M, Esene IN, Obamiro K.   +4 more
europepmc   +1 more source

Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs

Molecular Oncology, EarlyView.
In HGSOC with normal KRAS expression, high PTP4A3 expression regulates autophagy activation. Conversely, in HGSOC with high KRAS expression, KRAS dictates autophagy control, and PTP4A3 is not required. When high PTP4A3 expression is inhibited, HGSOC cells are preferentially sensitised towards DNA‐damaging agents.
Ana López‐Garza, David James, Emma Creagh, James T. Murray   +3 more
wiley   +1 more source

Humanizing CAR T-cell therapy in B-ALL. [PDF]

Blood Adv
Faramand R, Muffly L.
europepmc   +1 more source

Application of upper alf body irradiation (UHBI) and cyclophosphamide (CP) as adjuvant therapy in non-small cell bronchogenic carcinoma (NSCBC)

, 1984
Charles W. Scarantino, Frederick Richards, Milton Raben, Carolyn Ferree, Christina Kovacs, W Olds   +5 more
openalex   +1 more source

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer

Molecular Oncology, EarlyView.
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh, Liping Su, Suet Lin Chia, Xiaohe Tian, Haslina Ahmad, Martin R. Gill   +5 more
wiley   +1 more source

Navigating the manufacturing, testing and regulatory complexities of regulatory T cells for adoptive cell therapy. [PDF]

Front Immunol
Pikor LA, Arivazhagan S, Mendicino M, Sathiamoorthy S.   +3 more
europepmc   +1 more source